Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-27T14:28:00.609Z Has data issue: false hasContentIssue false
  • English
  • Français

Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer

Published online by Cambridge University Press:  12 March 2014

Samy M. AlGizawy ,
Hoda H. Essa ,
Mostafa E. Abdel-Wanis  and
Ahmed M. Abdel Raheem
Samy M. AlGizawy*
Affiliation:
Department of Clinical Oncology, Faculty of Medicine, Assiut University, Egypt
Hoda H. Essa
Affiliation:
Department of Clinical Oncology, Faculty of Medicine, Assiut University, Egypt
Mostafa E. Abdel-Wanis
Affiliation:
Department of Radiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University, Egypt
Ahmed M. Abdel Raheem
Affiliation:
Department of Urology, South Egypt Cancer Institute, Assiut University, Egypt
*
Correspondence to: Samy M. AlGizawy, MD, Assistant Professor, Department of Clinical Oncology, Faculty of Medicine, Assiut University, Assiut, Egypt. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Purpose

To compare the outcome among patients with invasive bladder cancer treated with cystectomy alone with outcome among those treated with combined-modality treatment in a randomised phase III trial.

Patients and methods

Patients with histologically confirmed invasive non-metastatic bladder cancer T2-3, N0 and M0 were randomly assigned to two arms: Arm 1: of which all patients underwent radical cystectomy (RC) alone; and Arm 2, of which all patients were subjected to maximal transurethral resection of bladder tumour, followed 2 weeks later by combined chemoradiotherapy. The whole pelvis received 46 Gy in 23 fractions over 4·5 weeks. Chemotherapy was administered concomitantly with radiotherapy with: cisplatin 70 mg/m2 q. 3 weeks and Gemcitabine 300 mg/m2 D 1, 8 and 15 q. 3 weeks for two cycles. Patients who had complete response were shifted to phase II treatment: 20 Gy/10 fractions/2 weeks to the bladder. Patients with residual tumour underwent RC.

Results

Of the 80 patients assigned Arm 2, a visibly completed transurethral resection of the bladder tumour was possible in 48 patients (60%). Phase I of combined chemoradiotherapy (CCRT) was accomplished in 74 patients. Post-induction urologic evaluation revealed no evidence of disease in 62 patients (83·8%) and residual disease in 12 patients (16·2%). Phase II of CCRT was completed in 58 of the 62 patients. The median follow-up for all patients is 27 months (range: 4–49). The 3-year overall survival (OS) for the combined-modality group and for the surgery group were 61 and 63%, respectively (p = 0·425), whereas the disease-specific survival (DSS) for each group was 69 and 73%, respectively (p = 0·714). The 3-year OS with bladder preservation for Arm 2 patients was 50%.

Multivariate analysis for the whole series showed that tumour stage and performance status (PS) were the only factors independently associated with DSS, although PS was the only factor independently associated with OS. In addition, residual disease after transurethral resection of the bladder tumour in Arm 2 patients was independently associated with both DSS and OS.

Acute toxicity was moderate and most of the late toxicities were grade 2 with no grade 4 toxicity and no treatment-related deaths, none required cystectomy for bladder contraction.

Conclusion

This study demonstrates that trimodality bladder-preserving approach represents a valid alternative for suitable patients. The OS and DSS rates of patients treated with trimodality bladder-preserving protocol are comparable to the results reported on patients treated with immediate radical cystectomy.

Keywords

bladder sparinginvasive bladder cancertrimodality approach
Type
Original Articles
Information
Journal of Radiotherapy in Practice , Volume 13 , Issue 4 , December 2014 , pp. 428 - 437
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. McDougal, W S, Shipley, W U, Kaufman, D S et al. Cancer of the bladder, ureter, and renal pelvis. In: DeVita V T, Lawrence T S, Rosenberg S A (eds). Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology, 8th edition. US: Lippincott Williams & Wilkins, 2008: 1358–1384.Google Scholar
2. Grossman, H B, Natale, R B, Tangen, C M et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349 (9): 859–866.CrossRefGoogle ScholarPubMed
3. Al Gizawy, S M, Essa, H H, Refaiy, A M, Elosaily, G M. Prognostic and predictive value of p53, bcl2, rb and EGFR for bladder preservation in invasive bladder carcinoma treated by trimodality approach. Kasr El-aini J Clin Oncol Nucl Med 2011; 7 (1-2): 40–49.CrossRefGoogle Scholar
4. Perdonà, S, Autorino, R, Damiano, R et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008; 112 (1): 75–83.CrossRefGoogle ScholarPubMed
5. Rodel, C, Weiss, C, Sauer, R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24 (35): 5536–5544.CrossRefGoogle ScholarPubMed
6. Kaufman, D S. Challenges in the treatment of bladder cancer. Annals Oncol 2006; 17 (Suppl. 5): v106–v112.CrossRefGoogle ScholarPubMed
7. Rödel, C, Weiss, C, Sauer, R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin Radiat Oncol 2004; 15: 28–35.CrossRefGoogle Scholar
8. Fernando, S A, Sandler, H M. Multimodality bladder preservation therapy for muscle-invasive bladder tumors. Semin Oncol 2007; 34: 129–134.CrossRefGoogle ScholarPubMed
9. Chung, P W M, Bristow, R G, Milosevic, M F et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007; 25: 303–309.CrossRefGoogle ScholarPubMed
10. Weiss, C, Engehausen, D G, Krause, F S et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1072–1080.CrossRefGoogle ScholarPubMed
11. Zietman, A L, Sacco, D, Skowronski, U et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long term survivors. J Urol 2003; 170: 1772–1776.CrossRefGoogle Scholar
12. Zapatero, A, Martin de Vidales, C, Arellano, R, Bocardo, G, Pérez, M, Ríos, P. Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 2010; 28: 368–374.CrossRefGoogle ScholarPubMed
13. Mekkawy, M A, Eid, S S, ElTaher, A M, Mostafa, H G, AbdulAziz, A M. Phase II study of concurrent chemo radiotherapy for bladder preservation in treatment of invasive bladder cancer. J Oncol Nucl Med 2006; 2: 373.Google Scholar
14. Shipley, W U, Kaufman, D S, Zehr, E et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60 (1): 62–67, discussion 67–68.CrossRefGoogle ScholarPubMed
15. Sabaa, M A, El-Gamal, O M, Abo-Elenen, M, Khanam, A. Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urol Oncol 2010; 28 (1): 14–20.CrossRefGoogle ScholarPubMed
16. Danesi, D T, Arcangeli, G, Crucian, E et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy long-term results. Cancer 2004; 101: 2540–2548.CrossRefGoogle ScholarPubMed
17. Herchenhorn, D, Dienstmann, R, Peixoto, F A et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol 2007; 33: 630–638.CrossRefGoogle ScholarPubMed
18. Zeitman, A L, Shipley, W U, Kaufman, D S et al. A Phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998; 160: 1673–1677.CrossRefGoogle Scholar
19. Kachnic, L A, Kaufmann, D S, Heney, N M et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 1022–1029.CrossRefGoogle ScholarPubMed
20. Perdona, S, Autorino, R, Damiano, R et al. Bladder-sparing, combined modality approach for muscle-invasive bladder cancer: a multi-institutional long-term experience. Cancer 2008; 112: 75–83.CrossRefGoogle ScholarPubMed
21. Weiss, C, Engehausen, D G, Krause, F S et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1072–1080.CrossRefGoogle ScholarPubMed
22. Kaufman, D S, Winter, K A, Shipley, W U et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000; 5 (6): 471–476.CrossRefGoogle ScholarPubMed
23. Shipley, W U, Zietman, A L, Kaufman, D S, Coen, J J, Sandler, H M. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates – the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005; 15 (1): 36–41.CrossRefGoogle ScholarPubMed
24. Khosravi-Shahi, P, Cabezón-Gutiérrez, L. Selective organ preservation in muscle-invasive bladder cancer: review of the literature. Surg Oncol 2012; 21 (1): e17–e22.CrossRefGoogle ScholarPubMed
25. Tunio, M A, Hashmi, A, Qayyum, A, Naimatullah, N, Mohsin, R, Sultan, G. Outcome of trimodality protocol for invasive bladder cancer patients at Karachi, Pakistan. J Pak Med Assoc 2011; 61 (9): 874–879.Google ScholarPubMed
26. Ibrahim, S M, Abd El-Hafeez, Z M, Mohamed, E M, Elsharawy, I A, Kamal, K M. Transurethral resection of bladder tumor (TUR-BT) then concomitant radiation and cisplatin followed by adjuvant gemcitabine and cisplatin in muscle invasive transitional cell carcinoma (TCC) of the urinary bladder. J Egypt Natl Canc Inst 2007; 19 (1): 77–86.Google ScholarPubMed
27. Shipley, W U, Kaufman, D S, Tester, W J et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 2003; 97: 2115–2119.CrossRefGoogle ScholarPubMed
28. Beena, K, Nambiar, R V, Dinesh, M. Tri-modality treatment in muscle invasive bladder cancer – what is the current status? Amrita J Med 2013; 9 (1): 16–23.Google Scholar
29. Efstathiou, J A, Spiegel, D Y, Shipley, W U et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012; 61: 705–711.CrossRefGoogle ScholarPubMed
30. Gakis, G, Efstathiou, J, Lerner, S P et al. ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013; 63 (1): 45–57.CrossRefGoogle ScholarPubMed
31. Krause, F S, Walter, B, Ott, O J et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 2011; 31 (3): 985–990.Google ScholarPubMed
32. Stein, J P, Lieskovsky, G, Kote, R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666–675.CrossRefGoogle Scholar
33. Dalbagni, G, Genega, E, Hashibe, M et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 1111–1116.CrossRefGoogle ScholarPubMed
34. Wijkstrom, H, Norning, U, Lagerkvist, M et al. Evaluation of clinical staging before cystectomy for transitional cell bladder carcinoma, a long-term follow-up of 276 consecutive patients. Br J Urol 1998; 81: 686–691.CrossRefGoogle ScholarPubMed
35. Nieuwenhuijzen, J A, Pos, F, Moonen, L M, Hart, A A, Horenblas, S. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005; 48 (2): 239–245.CrossRefGoogle ScholarPubMed